that PC cells have a higher capability to produce chemokines and function in an autocrine manner than inflammatory cells.
However, to the best of our knowledge, the present study is the first to demonstrate serum concentrations of CXCL8 in relation to those of its specific receptor CXCR2 in patients with PC. The aim of our study was to evaluate the diagnostic significance of serum CXCL8 and CXCR2 as potential novel tumor markers of PC in comparison with well-established tumor markers such as CA 19-9 and CEA, as well as with an inflammatory marker, C-reactive protein (CRP). In addition, correlations between serum levels of the tested proteins and the clinicopathological characteristics of the tumor were assessed. We also examined the relationship between potential risk factors (age, sex, serum levels of the proteins) and the prediction of PC. Moreover, we evaluated the diagnostic usefulness based on diagnostic sensitivity and specificity, accuracy, negative and positive predictive values (NPV and PPV), as well as the areas under the receiver operating characteristic curve (AUC) for CXCL8 and its receptor CXCR2 in comparison with other tested proteins (CRP, CA 19-9 CEA) was also evaluated. The current study is the continuation of our previous investigations in which we assessed whether serum levels of selected chemokines and their specific receptors might be used as potential tumor markers of esophageal carcinoma.
22, 23 On the other hand, in our previous studies we established the diagnostic and prognostic utility of other specific proteins, such as matrix metalloproteinase 9 (MMP-9) and its tissue inhibitor 1 (TIMP-1) as well as other cytokines, including macrophagecolony stimulating factor (M-CSF) in PC. 24, 25 PATIENTS AND METHODS The total study group included 76 patients: 42 patients with PC (17 women and 25 men, aged 35-84 years) and 34 healthy volunteers (14 women and 20 men, aged 22-76 years). Patients were diagnosed in the 2nd Department of General Surgery, Medical University of Bialystok, Poland. The clinical diagnosis of PC was based on the microscopic examination of tissue samples. PC was staged based on the TNM classification, presented by the International Union Against Cancer. 26 All patients with PC were divided into 4 subgroups, dependent on tumor stage (TNM), depth of tumor invasion (T factor), the presence of lymph node metastasis (N factor), and distant metastasis (M factor). The characteristics of PC patients are presented in TABLE 1. Informed consent was obtained from all patients and the present project was approved by the Local Ethics Committee (R-I-002/65/2017) of the Medical University of Bialystok.
Serum samples from PC patients were collected prior to the commencement of treatment and stored at -80ºC until assayed. Serum concentrations of CXCL8 and CXCR2 were measured using enzyme-linked immunosorbent assay (ELISA) kits in detecting early-stage disease, novel methods of diagnosis are critically needed. Carbohydrate antigen has been established as the most validated serum marker due to its high positive predictive value. In addition, the combined analysis of CA 19-9 with carcinoembryonic antigen (CEA) and CA 125 is useful in the prediction of patients' surgical and chemotherapy outcomes. 2 However, the usefulness of well-established serum biomarkers is unsatisfactory due to their low diagnostic sensitivity and specificity in the early stages of PC. Furthermore, there may be no correlations between imaging test results and concentrations of PC biomarkers. 2 Therefore, diagnosing PC at the early stage of the disease is crucial to improve patients' clinical outcomes.
A growing body of evidence has confirmed the significance of chronic inflammation in the development of various malignancies, including PC. 6 Chemokines are small chemotactic proteins that are involved in physiological and pathological processes, including inflammation and wound healing. 7-9 The family of chemokines has been divided into 4 groups (C, CC, CX3C, CXC), depending on the position of key cysteine residues. Some authors suggest that these proteins may promote the proliferation, migration, invasion, and angiogenesis of tumor cells. 10 -13 CXCL8, known as interleukin 8 (IL-8), belongs to the CXC chemokines, in which the 2 N-terminal cysteines are separated by one amino acid (X). CXCL8 might be produced by monocytes, T lymphocytes, neutrophils, natural killer cells, as well as fibroblasts and epithelial cells. This chemokine acts via its 2 specific receptors: CXCR1 and CXCR2. These proteins are G-protein-coupled receptors with 7 transmembrane domains comprised of 3 extracellular and 3 intracellular domains. The N-terminal domain is extracellular and is involved in chemokine binding. The most potent ligand of CXCR2 is CXCL8 as well as cleavage products of this chemokine. 14,15 CXCR2 is present on monocytes and neutrophils. 7-9,14 It has been proved that the CXCL8-CXCR2 axis is linked to inflammatory processes and might play a role in tumor progression and angiogenesis.
7,14 CXCL8 is known as a powerful promoter of tumor angiogenesis that binds to CXCR2, while its receptor, CXCR2, may regulate the response of endothelial cells to CXCL8. 8 Stromal and neoplastic cells are able to produce CXCL8, which promotes the invasion, metastasis, and, particularly, the angiogenic potential of a number of malignancies, including non-Hodgkin lymphomas as well as solid tumors such as pancreatic neoplasms. 16-20 An immunohistochemical study by Chen et al 21 revealed that the expression of CXCL8 and its specific receptor was higher in PC tissue in comparison with non-PC samples. The authors confirmed that CXCL8 was produced by PC cells. 21 Furthermore, serum CXCL8 levels in PC patients were significantly higher than in patients with other tumors of the digestive system as well as chronic and acute pancreatitis. 21 The authors concluded was employed if significant differences were observed. 27 The Spearman rank correlation test was used for correlation analyses. Furthermore, diagnostic parameters, including sensitivity, specificity, accuracy, NPV, and PPV for the tested proteins were also evaluated. The differences were considered as significant at a P value of less than 0.05. For statistical analysis, IBM SPSS Statistics 20.0 was used, whereas Microsoft Office Excel was used to calculate diagnostic parameters. Logistic regression was used to assess the strength of the association between various risk factors and PC. Univariate logistic regression models were used first to evaluate the relationship of each variable with PC risk. At the next step, variables with a P value of less than 0.05 were introduced into the multivariate model. Finally, the least significant variables were removed in a stepwise manner from the model based on the Wald statistic.
RESULTS Serum levels of the tested proteins (CXCL8, CXCR2, CA 19-9, CEA, and CRP) in patients with PC in comparison with healthy controls are presented in TABLE 2. CXCL8 and CXCR2 levels were higher in PC patients compared with healthy controls (P <0.001 and P = 0.003, respectively), similarly to CA 19-9 and CEA (P <0.001), as well as CRP (P <0.001) (FIGURE 1, TABLE 2) .
Following the analysis of the relationship between serum protein concentrations and the clinicopathological characteristics of the tumor, we established that CXCL8 and CXCR2 levels, similarly to CRP and CEA levels, were higher in the serum of patients with lymph node metastasis (N1 subgroup) and distant metastasis (M1 subgroup) in comparison with patients without nodal involvement (N0 subjects) and the presence of distant metastasis (M0 subjects) (TABLE 3) . However, a significant difference was found only between serum CXCL8 levels and nodal involvement (P = 0.046; FIGURE 2).
The results of the Spearman rank correlation analysis are presented in TABLE 4. Serum CXCL8 concentrations correlated with CRP levels (P = 0.01) and the presence of lymph node metastasis (P = 0.04) in PC patients.
To assess the diagnostic usefulness of CXCL8 and its receptor in PC patients, we calculated its sensitivity and specificity, accuracy, NPV and PPV, as well as AUC, and compared them with those of CA 19-9 and CEA. The percentage of elevated concentrations (diagnostic sensitivity) of CXCL8 was 98% and was higher than that of CXCR2, CA 19-9, CEA, and CRP (74%, 69%, 90%, and 62%, respectively) (FIGURE 3). The combined measurement of CXCL8 and CXCR2 or CXCL8 and the classic tumor markers increased the diagnostic sensitivity to 100%. Similar results were obtained for the NPV, which was also the highest for CXCL8. The diagnostic specificity of CXCL8 level measurement was 95% and was higher than that of CXCR2 and CEA, but marginally lower than that of CRP and CA 19-9 concentrations, similarly (Quantikine ELISA Human CXCL8/IL-8 Immunoassay, Abingdon, R&D Systems, United Kingdon and Human C-X-C chemokine receptor type 2, EIAab, Wuhan, China, respectively) in accordance with the manufacturer's instructions. Serum levels of CA 19-9 and CEA were measured with a microparticle immunoassay (Abbott, Abbott Park, Illinois United States) using ARCHI-TECT 8200 ci. Serum CRP levels were measured using the immunoturbidimetric method (AR-CHITECT 8200 ci, Abbott) in accordance with the manufacturer's instructions.
The Youden index was used to select the optimal predicted probability cutoff values. The reference cutoff values were 23.7 ng/ml for CXCL8, 0.72 ng/ml for CXCR2, 5.7 mg/l for CRP, 54.5 U/ml for CA 19-9, and 1.3 ng/ml for CEA.
Statistical analysis Serum CXCL8, CXCR2, CA 19-9, CEA, and CRP concentrations did not follow a normal distribution in the preliminary statistical analysis (χ 2 test). Therefore, the nonparametric statistical analyses were used. For the comparison between 2 groups, the Mann-Whitney test was used. The Kruskal-Wallis test was used for the analysis of 3 or more groups. The post hoc Dwass-Steele-Critchlow-Fligner test Data are presented as median (min-max). A P value of less than 0.05 was considered significant.
SI conversion factors: to convert CA 19-9 to kU/l, multiply by 1; CEA to µg/l, by 1; CRP to nmol/l, by 9.524; CXCL8 to µg/l, by 0.001; and CXCR2 to µg/l, by 1.
Abbreviations: CA 19-9, carcinoembryonic antigen 19-9; CEA, carcinoembryonic antigen; CRP, C-reactive protein; CXCL8, C-X-C motif chemokine 8; CXCR2, specific C-X-C motif chemokine receptor 2; PC, pancreatic cancer included in the multivariate model (results were presented as odd ratios [ORs] and P values). The concentrations of CXCL8 (OR = 1.653, P = 0.01), CXCR2 (OR = 3.839, P = 0.004), CA 19-9 (OR = 1.044, P = 0.02), CEA (OR = 1.743, P = 0.01), and CRP (OR = 1.573, P = 0.002), as well as age (OR = 1.125, P <0.001) were significant predictors of increased PC risk. Significant variables in the univariate logistic regression analysis were included in the multivariate model. Subsequently, the least significant variables were removed from the model in a stepwise manner. Therefore, in the final model only the serum CXCL8 level was a significant predictor of PC risk (OR = 1.653, P = 0.01).
to the PPV. In addition, the diagnostic accuracy of serum CXCL8 levels was also higher than that of the other proteins. The highest accuracy was calculated for the combined measurement of CXCL8 and CA 19-9 (97%) (data not shown). The AUC for CXCL8 (0.9898, P <0.001) was higher than that for CXCR2 (0.6989, P = 0.001), CA 19-9 (0.8480, P <0.001), CEA (0.7370, P <0.001), and CRP (0.8260, P <0.001) (FIGURE 4) . The cutoff values of all the tested proteins were estimated using the Youden index. The relationship between various risk factors and the risk of PC was first examined in the univariate analysis to identify risk factors to be The present study is a continuation of our previous investigations which focused on the role of specific proteins as candidates for tumor markers in gastrointestinal malignancies. 22-23 According to our knowledge, there have been no studies assessing the diagnostic and prognostic significance of both CXCL8 and its specific receptor CXCR2 in PC in comparison with the well-established tumor markers. In addition, we investigated the role of the CXCL8-CXCR2 axis in PC progression. In our present study, we demonstrated that the concentrations of CXCL8 and CXCR2, similarly to the well-established tumor markers and CRP, were significantly higher in PC patients compared with healthy controls. Our findings suggest that PC cells are able to produce CXCL8. Our results are similar to those of other authors who also observed increased levels of this chemokine DISCUSSION PC is a highly lethal disease, usually diagnosed at a late stage. It is estimated that more than 90% of patients with PC die from this malignancy. 28 Therefore, it is crucial to facilitate the early-stage diagnosis. It has been proved that endogenous cytokines, including selected chemokines and their specific receptors, might be produced by PC cells. In addition, these small peptides serve as autocrine growth factors as well as indicators of immune response to malignancy. 6 Moreover, CXCL8 may act as a prooncogenic effector in many malignancies, including PC.
21, 29 The most critical role of this chemokine is its powerful angiogenic potential and its ability to promote the invasion and metastasis of neoplastic cells; thus this chemokine may mimic functions of vascular endothelial growth factor. Serum M-CSF, MMP-9, and TIMP-1 levels, similarly to those of the classic tumor markers CA 19-9 and CEA, were significantly higher in patients with PC than in healthy controls. Also serum CXCR2 levels were higher in cancer patients compared with the control group, although the study was performed in patients with esophageal cancer. 23 Our current study demonstrated that CXCL8 concentrations were significantly higher in patients with lymph node metastasis in comparison with patients without nodal involvement, which was confirmed by the Spearman rank correlation test. Based on our present results, we conclude that elevated serum CXCL8 levels may serve as a predictor of nodal involvement in PC, and that they might be used as a marker of tumor progression when the results of imaging methods are inconclusive. Our findings are in line with those of Kuwada et al, 12 who also confirmed that CXCL8 might be an indicator of the invasiveness of PC although they used immunohistochemical techniques to investigate the expression of this protein in PC tissue. Contrasting results were reported by Kim et al, 32 who concluded that this chemokine is not correlated with inflammatory markers and is unable to predict the tumor progression pattern.
17-20
In our study, the sensitivity, accuracy, and NPV of serum CXCL8 concentrations were higher than those of CXCR2, CA 19-9, CEA, and CRP. Furthermore, the AUC for CXCL8 was the highest among all the tested proteins in PC patients. If we consider the diagnostic characteristics of all the proteins studied, we may conclude that serum CXCL8 is the best candidate for a tumor marker in the diagnosis of PC. However, our findings need to be confirmed in future studies due to some limitation such as the number of PC patients and control group.
The incidence rate of PC is estimated to be similar to its mortality rate; therefore, there is an urgent need to find a novel biomarker of PC.
33 Numerous papers have presented the expression of CXCL8 or its specific receptor in PC tissue using the labor-intensive immunohistochemical method. However, easy-to-perform, cost-effective, and noninvasive methods in the diagnosis of PC are essential. In conclusion, our study found that out of all the tested proteins, serum CXCL8 was the only significant predictor of PC risk in multiple logistic regression models. Based on diagnostic characteristics, serum CXCL8 seems to be a better marker in PC diagnosis than the classic tumor markers such as CA 19-9 or CEA. Our results confirm the significance of CXCL8 and its specific receptor in the pathogenesis of PC, but the role of the CXCL8-CXCR2 axis in this malignancy is very complicated. Despite the nonspecific nature of these molecules, further investigations are necessary to clarify whether this chemokine might be used as a potential tumor marker of PC.
